Hematologic Malignancy
Adult B Acute Lymphoblastic Leukemia
CI-CAN-00004348Explore in graph →
Hematologic12 active trials2 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00004348Explore in graph →
Clinical trials
59 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (8)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01139970 | Veliparib and Temozolomide in Treating Patients With Acute Leukemia | completed | Phase 1 | 66 | National Cancer Institute (NCI)NIH | 1 | Nov 20, 2025 | clinicaltrials |
| NCT03160079 | Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts | completed | Phase 1 / Phase 2 | 16 | University of California, San DiegoOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT02975687 | CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia | completed | Phase 1 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT01588015 | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant | completed | Phase 1 | 36 | City of Hope Medical CenterOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT01029366 | CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy | completed | Phase 1 | 26 | University of PennsylvaniaOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT01925131 | S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia | completed | Phase 1 | 50 | SWOG Cancer Research NetworkNETWORK | 1 | May 3, 2023 | clinicaltrials |
| NCT00061945 | Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 302 | National Cancer Institute (NCI)NIH | 1 | May 3, 2022 | clinicaltrials |
| NCT00866307 | Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011) | completed | Phase 1 | 104 | Children's Oncology GroupNETWORK | 3 | Apr 27, 2021 | clinicaltrials |
| NCT03097770 | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 | completed | Phase 1 / Phase 2 | 100 | Chinese PLA General HospitalOTHER | 1 | Sep 2, 2020 | clinicaltrials |
| NCT00918333 | Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 124 | Mayo ClinicOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT01326702 | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors | completed | Phase 1 / Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2019 | clinicaltrials |
| NCT02228772 | Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults | completed | Phase 1 | 19 | Massachusetts General HospitalOTHER | 1 | Nov 26, 2019 | clinicaltrials |
| NCT01567709 | Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma | completed | Phase 1 | 34 | National Cancer Institute (NCI)NIH | 1 | Apr 11, 2018 | clinicaltrials |
| NCT00052520 | Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 29, 2017 | clinicaltrials |
| NCT00608361 | Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery | completed | Phase 1 | 80 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2015 | clinicaltrials |
| NCT00010192 | Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Nov 20, 2025source: clinicaltrials